Inven2 — University of Oslo & Oslo University Hospital Technology Transfer Office

Inven2 is the technology transfer office (TTO) jointly owned by the University of Oslo and Oslo University Hospital, and the largest TTO in the Nordic region.

What it does: Inven2 evaluates around 200 invention disclosures a year from University of Oslo and Oslo University Hospital researchers and the South-Eastern Norway health trusts, files patents, negotiates licences, and helps spin out companies, reinvesting all proceeds back into research and innovation as it pays no dividend.

Results: over 2010-2020, Inven2 helped establish 55 start-ups, filed 260 new patent applications and signed 388 licence agreements, while the value of its start-up portfolio grew from about NOK 500 million in 2010 to NOK 15 billion in 2020. Its flagship spin-out, the cancer-drug developer Algeta, was acquired by Bayer in 2013 for roughly NOK 17.6 billion (about USD 2.9 billion) after its radiopharmaceutical Xofigo reached the market.

Why it's a good practice: it demonstrates how a university-hospital TTO with a non-dividend, reinvestment model can produce at least one internationally significant biotech exit alongside a steady pipeline of smaller spin-outs, with results tracked and published annually.

Read the full analysis: https://www.cnbc.com/2013/11/26/bayer-bids-24-billion-for-norways-algeta.html

Read the full analysis: https://www.cnbc.com/2013/11/26/bayer-bids-24-billion-for-norways-algeta.html